Related Experiment Videos
Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas
M D Bronstein1, N R Musolino, S Benabou
1Division of Functional Neurosurgery, Hospital das Clinicas, University of Sao Paulo Medical School, Brazil.
Abstract:
Two patients harboring invasive macroprolactinomas, on treatment with bromocriptine, developed cerebrospinal fluid rhinorrhea 16 and 17 months after the beginning of the medical therapy. Neither patient had previously been submitted to surgery or radiotherapy. The fistulae were surgically corrected. Cerebrospinal fluid leakage is a well-documented complication of pituitary tumors, mainly after surgery and/or radiotherapy, but the reports of its occurrence after primary treatment with bromocriptine are rare. Therefore, the possibility of this complication must be considered, especially in patients with invasive macroprolactinomas.
Insights
Cerebrospinal fluid rhinorrhea is a rare complication of invasive macroprolactinomas treated with bromocriptine. This condition, characterized by cerebrospinal fluid leakage, requires surgical correction and careful consideration in patient management.
Area of Science:
- Neuroendocrinology
- Neurosurgery
- Oncology
Background:
- Invasive macroprolactinomas are pituitary tumors that can cause significant health issues.
- Cerebrospinal fluid (CSF) rhinorrhea, or leakage, is a known complication of pituitary tumors, often associated with surgical or radiation treatments.
- While bromocriptine is a primary medical therapy for prolactinomas, its association with CSF rhinorrhea is infrequently reported.